FMR LLC & Abigail Johnson Trim United Therapeutics Stake to 4.939%
Ticker: UTHR · Form: SC 13G/A · Filed: Feb 9, 2024
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, portfolio-change
TL;DR
**FMR LLC and Abigail Johnson now own 4.939% of United Therapeutics, a slight dip but still a big chunk.**
AI Summary
FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in United Therapeutics Corp (UTHR). As of December 31, 2023, they collectively beneficially own 2,321,039 shares of common stock, representing 4.939% of the company. This is an amendment to a previous filing, indicating a slight decrease in their reported percentage ownership from prior filings, which could signal a minor shift in their investment strategy or portfolio rebalancing. For investors, this matters because FMR LLC is a significant institutional holder, and changes in their position can sometimes influence market sentiment or reflect their view on the company's future prospects.
Why It Matters
This filing shows a major institutional investor, FMR LLC, and its leader, Abigail P. Johnson, still hold a significant, but slightly reduced, stake in United Therapeutics, which can be seen as a vote of confidence, albeit a slightly diminished one.
Risk Assessment
Risk Level: low — This filing indicates a minor adjustment by a large institutional investor and does not suggest significant immediate risk to the company or its stock.
Analyst Insight
Investors should note that a major institutional holder like FMR LLC still has a substantial position in United Therapeutics, but the slight reduction in percentage ownership (implied by an amendment) suggests a re-evaluation or portfolio adjustment rather than a strong bullish or bearish signal. Keep an eye on future filings for further changes in their stake.
Key Numbers
- 2,321,039 — Shares Beneficially Owned (This is the total number of United Therapeutics common shares FMR LLC and Abigail P. Johnson collectively own as of December 31, 2023.)
- 4.939% — Percent of Class (This represents the percentage of United Therapeutics' total common stock outstanding that FMR LLC and Abigail P. Johnson beneficially own.)
- 2,288,360 — Sole Voting Power (FMR LLC) (This is the number of shares over which FMR LLC has sole voting power, indicating direct control over these specific shares.)
Key Players & Entities
- FMR LLC (company) — reporting person and parent holding company
- Abigail P. Johnson (person) — reporting person and principal owner of FMR LLC
- UNITED THERAPEUTICS Corp (company) — the subject company whose shares are being reported
- 2,321,039 (dollar_amount) — total shares beneficially owned by FMR LLC and Abigail P. Johnson
- 4.939% (dollar_amount) — percentage of class beneficially owned by FMR LLC and Abigail P. Johnson
Forward-Looking Statements
- FMR LLC will maintain a significant, but potentially fluctuating, stake in United Therapeutics Corp. (FMR LLC) — medium confidence, target: Next 12-18 months
FAQ
Who are the primary reporting persons in this SC 13G/A filing?
The primary reporting persons are FMR LLC and Abigail P. Johnson, as stated in Item 1 of the filing for both entities.
What is the total number of United Therapeutics Corp (UTHR) common shares beneficially owned by the reporting persons?
According to Item 4(a) for FMR LLC and Item 7 for Abigail P. Johnson, the total amount beneficially owned is 2,321,039 shares.
What percentage of United Therapeutics Corp's common stock do FMR LLC and Abigail P. Johnson collectively own?
Both FMR LLC and Abigail P. Johnson report owning 4.939% of the class, as indicated in Item 11 for both reporting persons.
What is the CUSIP number for United Therapeutics Corp's common stock?
The CUSIP number for United Therapeutics Corp's common stock is 91307C102, as listed in Item 2(e) of the filing.
Under which rule is this Schedule 13G filed?
This Schedule 13G is filed pursuant to Rule 13d-1(b), as indicated by the checked box in the filing and stated in Item 3.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on February 9, 2024 by Abigail P. Johnson regarding UNITED THERAPEUTICS Corp (UTHR).